Subgroup analysis showed that MSC-EV therapy significantly increased ALB in liver fibrosis, IRI, and NAFLD but not in ALI (P = 0.21) (Figure 2). Here, ALB is linked to metabolic dysfunction-associated steatotic liver disease.